The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Pollock, B. G.
* Articles by Chew, M. L.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Pollock, B. G.
* Articles by Chew, M. L.
Related Collections
* Stroke
* Antidepressants
* Other Neuroleptics
Am J Psychiatry 159:460-465, March 2002
© 2002 American Psychiatric Association


Article

Comparison of Citalopram, Perphenazine, and Placebo for the Acute Treatment of Psychosis and Behavioral Disturbances in Hospitalized, Demented Patients

Bruce G. Pollock, M.D., Ph.D., Benoit H. Mulsant, M.D., Jules Rosen, M.D., Robert A. Sweet, M.D., Sati Mazumdar, Ph.D., Ashok Bharucha, M.D., Robert Marin, M.D., N. J. Jacob, M.D., Kimberly A. Huber, B.A., Kari B. Kastango, M.S., and Marci L. Chew, B.S.

OBJECTIVE: Until recently, conventional antipsychotics were the standard pharmacotherapy for psychosis and behavioral disturbances associated with dementia. This double-blind, placebo-controlled study compared the acute efficacy of the selective serotonin reuptake inhibitor citalopram and the neuroleptic perphenazine with placebo for the treatment of psychosis and behavioral disturbances in nondepressed patients with dementia. METHOD: Eighty-five hospitalized patients with at least one moderate to severe target symptom (aggression, agitation, hostility, suspiciousness, hallucinations, or delusions) were randomly assigned to receive either citalopram, perphenazine, or placebo under double-blind conditions for up to 17 days. RESULTS: Patients treated with citalopram or perphenazine showed statistically significant improvement on several Neurobehavioral Rating Scale factor scores. Compared to those receiving placebo, only patients treated with citalopram showed significantly greater improvement in their total Neurobehavioral Rating Scale score as well as in the scores for the agitation/aggression and lability/tension factors. Side effect scores were similar among the three treatment groups. CONCLUSIONS: Citalopram was found to be more efficacious than placebo in the short-term hospital treatment of psychotic symptoms and behavioral disturbances in nondepressed, demented patients.




This article has been cited by other articles:


Home page
Arch Gen PsychiatryHome page
R. A. Rosenheck, D. L. Leslie, J. L. Sindelar, E. A. Miller, P. N. Tariot, K. S. Dagerman, S. M. Davis, B. D. Lebowitz, P. Rabins, J. K. Hsiao, et al.
Cost-Benefit Analysis of Second-Generation Antipsychotics and Placebo in a Randomized Trial of the Treatment of Psychosis and Aggression in Alzheimer Disease
Arch Gen Psychiatry, November 1, 2007; 64(11): 1259 - 1268.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
A. T. Blaszczyk and M. Mathys
Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia
Journal of Pharmacy Practice, February 1, 2007; 20(1): 13 - 28.
[Abstract] [PDF]


Home page
NEJMHome page
L. S. Schneider, P. N. Tariot, K. S. Dagerman, S. M. Davis, J. K. Hsiao, M. S. Ismail, B. D. Lebowitz, C. G. Lyketsos, J. M. Ryan, T. S. Stroup, et al.
Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease.
N. Engl. J. Med., October 12, 2006; 355(15): 1525 - 1538.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. L. Cummings
Neuropsychiatric and behavioral alterations and their management in moderate to severe Alzheimer disease
Neurology, September 27, 2005; 65(6_suppl_3): S18 - S24.
[Full Text]


Home page
Evid. Based Ment. HealthHome page
B. H Mulsant
Review: pharmacotherapy provides minimal improvements in the neuropsychiatric symptoms of dementia
Evid. Based Ment. Health, August 1, 2005; 8(3): 83 - 83.
[Full Text] [PDF]


Home page
JAMAHome page
M. Steinberg and C. Lyketsos
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia
JAMA, May 11, 2005; 293(18): 2211 - 2212.
[Full Text] [PDF]


Home page
JAMAHome page
K. M. Sink, K. F. Holden, and K. Yaffe
Pharmacological Treatment of Neuropsychiatric Symptoms of Dementia: A Review of the Evidence
JAMA, February 2, 2005; 293(5): 596 - 608.
[Abstract] [Full Text] [PDF]


Home page
J PsychopharmacolHome page
N. Herrmann, K. L. Lanctot, G. Eryavec, and L. R. Khan
Noradrenergic Activity is Associated with Response to Pindolol in Aggressive Alzheimer's Disease Patients
J Psychopharmacol, June 1, 2004; 18(2): 215 - 220.
[Abstract] [PDF]


Home page
J Geriatr Psychiatry NeurolHome page
J. Mintzer and S. D. Targum
Psychosis in Elderly Patients: Classification and Pharmacotherapy
J Geriatr Psychiatry Neurol, December 1, 2003; 16(4): 199 - 206.
[Abstract] [PDF]


Home page
J Geriatr Psychiatry NeurolHome page
N. Hoeh, L. Gyulai, D. Weintraub, and J. Streim
Pharmacologic Management of Psychosis in the Elderly: A Critical Review
J Geriatr Psychiatry Neurol, December 1, 2003; 16(4): 213 - 218.
[Abstract] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
G. T. Grossberg and A. K. Desai
Management of Alzheimer's Disease
J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2003; 58(4): M331 - 353.
[Full Text] [PDF]


Home page
Psychiatr. NewsHome page
J. Rosack
SSRI Improves Behavior Symptoms In Demented Elderly Patients
Psychiatr News, April 5, 2002; 37(7): 28 - 28.
[Full Text]




Get information about faster international access.

Privacy Policy

Copyright © 2002 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org